LIXTE Biotechnology Appoints Sidney Braun as CEO of European Subsidiary to Advance Proton Therapy Platform

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical and med-tech company advancing cancer treatments, announced the appointment of Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary. Braun, who previously facilitated LIXTE’s November 2025 acquisition of Liora’s assets, brings more than 20 years of healthcare operational and strategic advisory experience and will lead advancement of Liora’s LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment. Management said the appointment supports its strategy to scale the technology and pursue a recurring revenue model within the radiotherapy segment of cancer care.

The appointment of Braun represents a strategic move to accelerate development of the LiGHT System, which represents a significant advancement in proton therapy technology. Proton therapy is a precise form of radiation treatment that targets tumors while minimizing damage to surrounding healthy tissue, making it particularly valuable for treating cancers in sensitive areas. The LiGHT System’s electronic control mechanism aims to improve the precision and efficiency of this treatment modality, potentially offering better outcomes for cancer patients. By placing Braun, with his extensive experience in healthcare operations and his prior involvement in the acquisition, at the helm of the European subsidiary, LIXTE is positioning itself to more effectively commercialize this technology in key international markets.

This leadership change is directly tied to LIXTE’s broader corporate strategy of building a diversified portfolio of cancer therapies. The company’s primary focus remains on its first-in-class lead clinical PP2A inhibitor, LB-100, which has shown promise in enhancing chemotherapies and immunotherapies. Proof-of-concept clinical trials for LB-100 are currently in progress for specific cancer types, as detailed in the company’s published preclinical data available at https://www.lixte.com. The development of the LiGHT System through the Liora subsidiary represents a parallel path in the med-tech space, addressing the radiotherapy segment. This dual approach in both pharmaceutical and device-based treatments could provide LIXTE with multiple revenue streams and a more comprehensive offering in the oncology market.

The implications of this executive appointment extend beyond corporate structure. For the cancer care landscape, the successful scaling of the LiGHT System could make advanced proton therapy more accessible and effective. A recurring revenue model in radiotherapy suggests a shift toward service-based or maintenance contracts for medical institutions utilizing the technology, which could provide LIXTE with more predictable long-term income. Investors and stakeholders can follow further developments through the company’s official communications. The strategic importance lies in leveraging Braun’s expertise to transform an acquired asset into a commercially viable product that complements LIXTE’s existing drug development pipeline, thereby strengthening the company’s overall position in advancing cancer treatment options.